Literature DB >> 18951493

Innate and adaptive immune activation in the brain of MPS IIIB mouse model.

Julianne DiRosario1, Erin Divers, Chuansong Wang, Jonathan Etter, Alyssa Charrier, Peter Jukkola, Herbert Auer, Victoria Best, David L Newsom, Douglas M McCarty, Haiyan Fu.   

Abstract

Mucopolysaccharidosis (MPS) IIIB is a lysosomal storage disease with severe neurological manifestations due to alpha-N-acetylglucosaminidase (NaGlu) deficiency. The mechanism of neuropathology in MPS IIIB is unclear. This study investigates the role of immune responses in neurological disease of MPS IIIB in mice. By means of gene expression microarrays and real-time quantitative reverse transcriptase-polymerase chain reaction, we demonstrated significant up-regulation of numerous immune-related genes in MPS IIIB mouse brain involving a broad range of immune cells and molecules, including T cells, B cells, microglia/macrophages, complement, major histocompatibility complex class I, immunoglobulin, Toll-like receptors, and molecules essential for antigen presentation. The significantly enlarged spleen and lymph nodes in MPS IIIB mice were due to an increase in splenocytes/lymphocytes, and functional assays indicated that the T cells were activated. An autoimmune component to the disease was further suggested by the presence of putative autoantigen or autoantigens in brain extracts that reacted specifically with serum IgG from MPS IIIB mice. We also demonstrated for the first time that immunosuppression with prednisolone alone can significantly slow the central nervous system disease progression. Our data indicate that immune responses contribute greatly to the neuropathology of MPS IIIB and should be considered as an adjunct treatment in future therapeutic developments for optimal therapeutic effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18951493     DOI: 10.1002/jnr.21912

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  44 in total

Review 1.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

2.  Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB.

Authors:  Coy D Heldermon; Kevin K Ohlemiller; Erik D Herzog; Carole Vogler; Elizabeth Qin; David F Wozniak; Yun Tan; John L Orrock; Mark S Sands
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Near-Complete Correction of Profound Metabolomic Impairments Corresponding to Functional Benefit in MPS IIIB Mice after IV rAAV9-hNAGLU Gene Delivery.

Authors:  Haiyan Fu; Aaron S Meadows; Tierra Ware; Robert P Mohney; Douglas M McCarty
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

Review 4.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 5.  Mucopolysaccharide diseases: a complex interplay between neuroinflammation, microglial activation and adaptive immunity.

Authors:  Louise D Archer; Kia J Langford-Smith; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2013-05-08       Impact factor: 4.982

6.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

Review 7.  Recent trends in mucopolysaccharidosis research.

Authors:  Hiroshi Kobayashi
Journal:  J Hum Genet       Date:  2018-11-19       Impact factor: 3.172

8.  Thymic alterations in GM2 gangliosidoses model mice.

Authors:  Seiichi Kanzaki; Akira Yamaguchi; Kayoko Yamaguchi; Yoshitsugu Kojima; Kyoko Suzuki; Noriko Koumitsu; Yoji Nagashima; Kiyotaka Nagahama; Michiko Ehara; Yoshio Hirayasu; Akihide Ryo; Ichiro Aoki; Shoji Yamanaka
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

9.  Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response.

Authors:  Smruti Killedar; Julianne Dirosario; Erin Divers; Phillip G Popovich; Douglas M McCarty; Haiyan Fu
Journal:  J Neuroinflammation       Date:  2010-07-16       Impact factor: 8.322

10.  Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease.

Authors:  Marcelina Malinowska; Fiona L Wilkinson; Kia J Langford-Smith; Alex Langford-Smith; Jillian R Brown; Brett E Crawford; Marie T Vanier; Grzegorz Grynkiewicz; Rob F Wynn; J Ed Wraith; Grzegorz Wegrzyn; Brian W Bigger
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.